ArticleFrontiers in oncology2026
Primary central nervous system lymphoma and tumefactive demyelinating lesions in multiple sclerosis: a retrospective observational cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiating primary central nervous system lymphoma (PCNSL) from tumefactive demyelinating lesions (TDLs) remains a major diagnostic challenge. Objective: Our study aimed to compare the differences in clinical observations, neuroimaging data, and pathological features between the PCNSL and TDLs, as well as their potential biomarkers. Method: This was a retrospective observational cohort study of 183 patients (97 PCNSL and 86 TDLs). Baseline clinical data were collected. Neuroimaging features were determined by MRI. Pathological characteristics were evaluated by using hematoxylin-eosin (HE) staining, and immunochemical staining of CD3 and CD20. Cerebrospinal fluid (CSF) and serum biomarkers were detected by using the commercial protein assay kit and the enzyme-linked immunosorbent assay. Results: Patients with PCNSL had an older onset age, with the mean age being 59 ± 10 years in the PCNSL group and 36 ± 8 years in the TDL group (p < 0.001). Upon MRI scans, brain lesions in PCNSL showed U-shaped hyperintense, while lesions in TDLs showed slightly diffuse hyperintense on diffusion-weighted imaging (DWI) sequence. PCNSL lesions showed obvious hyperintense and perifocal edema, while TDL lesions showed isointense with partial perifocal edema on fluid attenuated inversion recovery (FLAIR) sequences. CD20 was strongly positive, while CD3 was negative in PCNSL tissues, which was different from a lower CD20 and stronger CD3 levels in TDLs. IL-6 and IL-10 levels was higher in the CSF of PCNSL than TDLs. Conclusion: Careful and comprehensive evaluation of clinical, neuroimaging, and pathological features, and CSF IL-6 and IL-10 levels facilitates the differential diagnosis betweenPCNSL and TDLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.